Correlation between blood lipid and homocysteine and cognitive impairment in Parkinson's disease

doi:10.3969/j.issn.1004-583X.2022.02.006

Abstract

Abstract:

Objective To investigate the correlation between the levels of blood lipid and homocysteine (Hcy) and the degree of cognitive impairment in Parkinson's disease (PD).Methods A total of 100 PD patients and 50 healthy people admitted to the Department of Neurology of Jinzhou Central Hospital during Sept 2019 - Aug 2021 were respectively registered into PD group and control group. According to the score of Montreal cognitive Assessment(MoCA), patients in PD group were divided into 38 patients with normal cognition (PD-NC), 32 patients with mild cognitive impairment (PD-MCI) and 30 patients with PD dementia (PDD). The aim was to detect levels of blood lipid and serum Hcy of all patients, explore the differences of indicators between groups, and analyze the correlation between the above indicators and the degree of cognitive impairment.Results Compared with control group, PD group had significantly higher level of Hcy (P<0.05), lower levels of total cholesterol (TC), triglyceride (TG) and low density lipoprotein cholesterol(LDL-C) (P<0.05), significant differences existed in the levels of TG, LDL-C and Hcy among PD-NC subgroup, PD-MCI subgroup and PDD subgroup (P < 0.05). Logistic regression analysis showed that Hcy was an independent risk factor for PD cognitive impairment (P<0.05).Conclusion There is a certain correlation between the levels of TG, LDL-C and Hcy and the degree of cognitive impairment for PD patients.

Key words: Parkinson's disease, cognitive impairment, blood lipids, homocysteine

CLC Number:

R742.5

Guo Chang, Shen Huinan, Sun Yimeng, Wang Dongyu. Correlation between blood lipid and homocysteine and cognitive impairment in Parkinson's disease[J]. Clinical Focus, 2022, 37(2): 128-132.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.02.006

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I2/128

Figures/Tables 3

References 32

[1]	Triantafyllou NI, Nikolaou C, Boufidou F, et al. Folate and vitamin B12 levels in levodopa-treated Parkinson's disease patients: Their relationship to clinical manifestations, mood and cognition[J]. Parkinsonism Relat Disord, 2008,14(4):321-325. doi: 10.1016/j.parkreldis.2007.10.002 URL
[2]	Brandão PRP, Munhoz RP, Grippe TC, et al. Cognitive impairment in Parkinson's disease: A clinical and pathophysiological overview[J]. Neurol Sci, 2020,419:117177.
[3]	Pedersen KF, Larsen JP, Tysnes OB, et al. Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study[J]. Neurology, 2017,88(8):767-774. doi: 10.1212/WNL.0000000000003634 pmid: 28108638
[4]	常庆庆, 李红燕. 帕金森病患者血脂、胱抑素C及同型半胱氨酸水平分析[J]. 中国临床神经科学, 2018,26(5):495-501.
[5]	陈南耀, 蔡毅. 血清脂类指标与帕金森病合并认知障碍的关系研究[J]. 实用预防医学, 2014,21(10):1269-1271.
[6]	周超宁, 党小利, 陈军, 等. 帕金森病患者血尿酸及血同型半胱氨酸水平与认知障碍的关系[J]. 中国老年学杂志, 2019,39(15):3716-3719.
[7]	Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease[J]. Mov Disord, 2015,30(12):1591-1601. doi: 10.1002/mds.26424 URL
[8]	Estrada-Orihuela SF, Ibarra-Pérez C. Lasalocid immediately and completely prevents the myocardial damage caused by coronary ischemia reperfusion in rat heart[J]. Mol Cell Biochem, 2019,453(1-2):121-130. doi: 10.1007/s11010-018-3437-2 pmid: 30191481
[9]	Panicker N, Sarkar S, Harischandra DS, et al. Fyn kinase regulates misfolded α-synuclein uptake and NLRP3 inflammasome activation in microglia[J]. Exp Med, 2019,216(6):1411-1430. doi: 10.1084/jem.20182191 URL
[10]	Sliter DA, Martinez J, Hao L, et al. Parkin and PINK1 mitigate STING-induced inflammation[J]. Nature, 2018,561(7722):258-262. doi: 10.1038/s41586-018-0448-9 URL
[11]	Nasution RA, Islam AA, Hatta M, et al. Role of CAPE in reducing oxidative stress in animal models with traumatic brain injury[J]. Ann Med Surg (Lond), 2020,57:118-122. doi: 10.1016/j.amsu.2020.07.036 pmid: 32760580
[12]	Saedi S, Hemmati-Dinarvand M, Barmaki H, et al. Serum lipid profile of Parkinson's disease patients: A study from the Northwest of Iran[J]. Caspian J Intern Med, 2021,12(2):155-161.
[13]	王台, 史长河, 毛澄源, 等. 帕金森病与血清尿酸、同型半胱氨酸水平的相关性研究[J]. 中风与神经疾病杂志, 2021,38(4):117-121.
[14]	Gaig C, Tolosa E. When does Parkinson's disease begin?[J]. Mov Disord, 2009,24(Suppl 2):S656-S664. doi: 10.1002/mds.v24.2s URL
[15]	Berg AL, Rafnsson AT, Johannsson M, et al. The effects of adrenocorticotrophic hormone and an equivalent dose of cortisol on the serum concentrations of lipids, lipoproteins, and apolipoproteins[J]. Metabolism, 2006,55(8):1083-1087. doi: 10.1016/j.metabol.2006.04.001 URL
[16]	Fu X, Wang Y, He X, et al. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson's disease[J]. Lipids Health Dis, 2020,19(1):97. doi: 10.1186/s12944-020-01284-w URL
[17]	戚志强, 张克忠, 王圣龙, 等. 帕金森病患者血脂水平的变化及其临床相关性研究[J]. 中华老年心脑血管病杂志, 2016,18(2):119-121.
[18]	Sharma JC, Macnamara L, Hasoon M, et al. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade)[J]. Parkinsonism Relat Disord, 2006,12(8):499-505. doi: 10.1016/j.parkreldis.2006.07.002 URL
[19]	Mather M, Harley CW. The locus coeruleus: Essential for maintaining cognitive function and the aging brain[J]. Trends Cogn Sci, 2016,20(3):214-226. doi: S1364-6613(16)00018-8 pmid: 26895736
[20]	Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies[J]. Nat Rev Neurosci, 2013,14(9):626-636. doi: 10.1038/nrn3549 URL
[21]	Fantini J, Carlus D, Yahi N. The fusogenic tilted peptide (67-78) of α-synuclein is a cholesterol binding domain[J]. Biochim Biophys Acta[J]. 2011,1808(10):2343-2351.
[22]	Banks WA, Farr SA, Salameh TS, et al. Triglycerides cross the blood-brain barrier and induce central leptin and insulin receptor resistance[J]. Int J Obes (Lond), 2018,42(3):391-397. doi: 10.1038/ijo.2017.231 URL
[23]	Nägga K, Gustavsson AM, Stomrud E, et al. Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later[J]. Neurology, 2018,90(1):e73-e81. doi: 10.1212/WNL.0000000000004749 URL
[24]	Gao J, Huang X, Park Y, et al. Apolipoprotein E genotypes and the risk of Parkinson disease[J]. Neurobiol Aging, 2011, 32(11):2106.e1-6. doi: 10.1016/j.neurobiolaging.2011.05.016 URL
[25]	Johansen CT, Wang J, Lanktree MB, et al. An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia[J]. Arterioscler Thromb Vasc Biol, 2011,31(8):1916-1926. doi: 10.1161/ATVBAHA.111.226365 URL
[26]	Chaudhary R, Likidlilid A, Peerapatdit T, et al. Apolipoprotein E gene polymorphism: Effects on plasma lipids and risk of type 2 diabetes and coronary artery disease[J]. Cardiovasc Diabetol, 2012,11:36. doi: 10.1186/1475-2840-11-36 pmid: 22520940
[27]	Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, et al. Homocysteine and cognitive impairment in Parkinson's disease: A biochemical, neuroimaging, and genetic study[J]. Mov Disord, 2009,24(10):1437-1444. doi: 10.1002/mds.22522 URL
[28]	Song IU, Kim JS, Park IS, et al. Clinical significance of homocysteine (hcy) on dementia in Parkinson's disease (PD)[J]. Arch Gerontol Geriatr, 2013,57(3):288-291. doi: 10.1016/j.archger.2013.04.015 URL
[29]	Sleeman I, Lawson RA, Yarnall AJ, et al. Urate and homocysteine: Predicting motor and cognitive changes in newly diagnosed parkinson's disease[J]. J Parkinson’s Dis, 2019,9(2):351-359.
[30]	Ho PI, Ortiz D, Rogers E, et al. Multiple aspects of homocysteine neurotoxicity: Glutamate excitotoxicity, kinase hyperactivation and DNA damage[J]. J Neurosci Res, 2002,70(5):694-702. doi: 10.1002/(ISSN)1097-4547 URL
[31]	Obeid R, Schadt A, Dillmann U, et al. Methylation status and neurodegenerative markers in Parkinson disease[J]. Clin Chem, 2009,55(10):1852-1860. doi: 10.1373/clinchem.2009.125021 pmid: 19679632
[32]	彭雪梅, 邓婧, 李琴, 等. 帕金森病患者血尿酸水平与认知功能、炎性因子及神经细胞因子的相关性[J]. 疑难病杂志, 2019,18(2):119-122.

组别	例数	TG(mmol/L)	TC(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	Hcy(μmol/L)
对照组	50	1.45±0.35	4.74±0.93	1.35±0.20	2.87±0.60	9.67±2.67
PD组	100	1.29±0.44^*	4.34±0.91^*	1.28±0.28	2.55±0.48^*	15.03±5.51^*
t值		2.373	2.469	1.804	3.626	-8.021
P值		0.019	0.015	0.074	0.000	0.000

组别	例数	TG(mmol/L)	TC(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	Hcy(μmol/L)
对照组	50	1.45±0.35	4.74±0.93	1.35±0.20	2.87±0.60	9.67±2.67
PD组	100	1.29±0.44^*	4.34±0.91^*	1.28±0.28	2.55±0.48^*	15.03±5.51^*
t值		2.373	2.469	1.804	3.626	-8.021
P值		0.019	0.015	0.074	0.000	0.000

组别	例数	TG(mmol/L)	TC(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	Hcy(μmol/L)
PD-NC亚组	38	1.15±0.42	4.13±0.86	1.31±0.28	2.40±0.46	12.18±4.22
PD-MCI亚组	32	1.29±0.46	4.36±0.95	1.24±0.29	2.58±0.46	15.27±4.48^*
PDD亚组	30	1.49±0.40^*	4.60±0.90	1.28±0.27	2.69±0.50^*	18.38±6.11^*#
F值		5.070	2.249	0.564	3.276	13.284
P值		0.008	0.111	0.571	0.042	0.000

组别	例数	TG(mmol/L)	TC(mmol/L)	HDL-C(mmol/L)	LDL-C(mmol/L)	Hcy(μmol/L)
PD-NC亚组	38	1.15±0.42	4.13±0.86	1.31±0.28	2.40±0.46	12.18±4.22
PD-MCI亚组	32	1.29±0.46	4.36±0.95	1.24±0.29	2.58±0.46	15.27±4.48^*
PDD亚组	30	1.49±0.40^*	4.60±0.90	1.28±0.27	2.69±0.50^*	18.38±6.11^*#
F值		5.070	2.249	0.564	3.276	13.284
P值		0.008	0.111	0.571	0.042	0.000

危险因素	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
危险因素	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
TG	0.625	0.582	1.154	0.283	1.869	0.597	5.850
LDL-C	0.156	0.562	0.077	0.781	1.169	0.389	3.515
Hcy	0.169	0.056	8.950	0.003	1.184	1.060	1.322